March 1, 2017
Lilly buys CoLucid Pharmaceuticals
Eli Lilly has completed acquisition of CoLucid Pharmaceuticals at a price of $46.50 per share through a second-step merger.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: CoLucid Pharmaceuticals
January 31, 2017
Lilly’s Q4 net income up 61%
Driven by new products, including Trulicity, Cyramza, Jardiance and Taltz, Lilly’s volume-driven significant growth in 2016.